Keywords: GlaxoSmithKline, Albiglutide, Type 2 diabetes, Regulatory filings, Ph III, Merck & Co, Januvia

GlaxoSmithKline readies for filing of diabetes drug albiglutide on positive final data

Article | 12 July 2012

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) says that positive data from the Phase III Harmony 8 study and from the event ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in